NORD is dedicated to supporting education, elevating care, advancing research, and driving policy for rare diseases
NORD is dedicated to supporting education, elevating care, advancing research, and driving policy for rare diseases
MedicalThe National Organization for Rare Disorders. Tarlov Cysts [internet].2012, June [citado el 7 de Nov. de 2014]. Disponible desde: http://www.National Organization for Rare Disorders (NORD). http://www.rarediseases.org/docs/NewsletterFall2010.pdf (accessed January 8, 2012)....
The Relationship between Oral Health and Brain Function WATANABE Makoto 日本歯科医学会誌 = Journal of the Japanese Association for Dental Science : JJDS (28), 60-63, 2009-03-31Maud GancelWassilios MeissnerFrançois Tison日本歯科医学会誌...
Loading...
EUROPLAN: a project to support the development of national plans on rare diseases in Europe. National Plans for Rare Diseases (RDs) are the common denominator of current public health policy concerns on RDs across the EU. With the aim of a better d... Taruscio,A E,Gentile,... - 《Pub...
The European Commission, recognizing that a number of healthcare and knowledge issues are common to all rare diseases in spite of the wide variety of their clinical manifestation, has recently initiated the promotion of national plans and comprehensive strategies for improving the provision of care ...
Neglected Diseases National Institutes of Health Announces New Program To Develop Therapeutics For Rare And Neglected DiseasesNational Institutes of Health Announces New Program To Develop Therapeutics For Rare And Neglected DiseasesGeoffrey Spencer
Shaw-Smith C: Genetic factors in esophageal atresia, tracheo-esophageal fistula and the VACTERL association: roles for FOXF1 and the 16q24.1 FOX transcription factor gene cluster, and review of the literature. Eur J Med Genet. 2010, 53: 6-13. 10.1016/j.ejmg.2009.10.001. Article PubMed Pu...
The 2023 NRDL Revision Work Plan (“2023 Work Plan”) maintained this policy, allowing all orphan drugs that obtained NMPA approval for market authorization before June 30, 2023, to apply for inclusion in the 2023 NRDL. Furthermore, the generic drugs for rare diseases listed in th...